drugset / Trial / NCT04042597
Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
Phase 2
Unknown
60 enrolled
Peking University People's Hospital
Beijing Jishuitan Hospital · collabCancer Institute and Hospital, Chinese Academy of Medical Sciences · collabChinese PLA General Hospital · collabPeking University Cancer Hospital & Institute · collabPeking University First Hospital · collabPeking University Shougang Hospital · collabPeking University Third Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. Anlotinib is a novel tyrosine kinase inhibitor targeting both at VEGFR-2, -3 and PDGFRA and PDGFRB with high affinity, which also showed broad antitumor activity against EGFR and so on. Thus this multicenter, two-armed phase II trial of PKUPH-sarcoma 05 intended to investigate the efficacy and safety of anlotinib versus imatinib on advanced chordoma.
Timeline
- Start
- 2019-07-18
- Primary completion
- 2021-10-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |